Review





Similar Products

98
ATCC human cscc cell lines a431 cells
Human Cscc Cell Lines A431 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cscc+cell+lines/A-431/pm42277814-212-0-7
Average 98 stars, based on 1 article reviews
human cscc cell lines a431 cells - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

98
ATCC human cscc cell lines a431
Human Cscc Cell Lines A431, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cscc+cell+lines/A-431/pm42215448-60-7-12
Average 98 stars, based on 1 article reviews
human cscc cell lines a431 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

86
Procell Inc human cscc cell lines siha
Human Cscc Cell Lines Siha, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cscc+cell+lines/bronchial+cells+epithelial+human/pm42119178-45-0-7
Average 86 stars, based on 1 article reviews
human cscc cell lines siha - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

96
ATCC human cscc cell line scl1
Human Cscc Cell Line Scl1, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cscc+cell+lines/Clone+of+Human+cell+Line+6D9/pm41257862-99-1-10
Average 96 stars, based on 1 article reviews
human cscc cell line scl1 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
ATCC human cscc ic8 cell line
Human Cscc Ic8 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cscc+cell+lines/Clone+of+Human+cell+Line+6D9/pm40836096-807-6-27
Average 96 stars, based on 1 article reviews
human cscc ic8 cell line - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

97
ATCC human cscc cell lines
Oncolytic activity of CVB3/2035A in human <t>CSCC</t> cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice <t>bearing</t> <t>C33A,</t> SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001
Human Cscc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cscc+cell+lines/Ca+Ski/pmc11452971-40-1-13
Average 97 stars, based on 1 article reviews
human cscc cell lines - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

Image Search Results


Oncolytic activity of CVB3/2035A in human CSCC cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice bearing C33A, SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001

Journal: Virology Journal

Article Title: Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel

doi: 10.1186/s12985-024-02502-y

Figure Lengend Snippet: Oncolytic activity of CVB3/2035A in human CSCC cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice bearing C33A, SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001

Article Snippet: Three human CSCC cell lines (C33A, SiHa, and CaSki) were purchased from the American Type Culture Collection (ATCC).

Techniques: Activity Assay, Derivative Assay, Infection, CCK-8 Assay, Control